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Objective: Depressive symptoms are associated with mortality among patients on chronic dialysis therapy. It
is currently unknown how different courses of depressive symptoms are associated with both cardiovascular
and non-cardiovascular mortality.
Methods: In a Dutch prospective nation-wide cohort study among incident patients on chronic dialysis, 1077
patients completed the Mental Health Inventory, both at 3 and 12 months after starting dialysis. Cox regres-
sion models were used to calculate crude and adjusted hazard ratios (HRs) for mortality for patients with de-
pressive symptoms at 3 months only (baseline only), at 12 months only (new-onset), and both at 3 and
12 months (persistent), using patients without depressive symptoms at 3 and 12 months as reference group.
Results: Depressive symptoms at baseline only seemed to be a strong marker for non-cardiovascular mortality
(HRadj 1.91, 95% CI 1.26–2.90), whereas cardiovascular mortality was only moderately increased (HRadj 1.41,
95% CI 0.85–2.33). In contrast, new-onset depressive symptoms were moderately associated with both cardio-
vascular (HRadj 1.66, 95% CI 1.06–2.58) and non-cardiovascular mortality (HRadj 1.46, 95% CI 0.97–2.20).
Among patients with persistent depressive symptoms, a poor survival was observed due to both cardiovascular
(HRadj 2.14, 95% CI 1.42–3.24) and non-cardiovascular related mortality (HRadj 1.76, 95% CI 1.20–2.59).
Conclusion: This study showed that different courses of depressive symptoms were associated with a poor sur-
vival after the start of dialysis. In particular, temporary depressive symptoms at the start of dialysis may be a
strong marker for non-cardiovascular mortality, whereas persistent depressive symptoms were associated
with both cardiovascular and non-cardiovascular mortality.© 2013 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Evidence suggests that depressive symptoms are associated with
mortality in patients with end-stage renal disease (ESRD) treated with
dialysis therapy, even after adjustment for a wide array of covariates
[1–5]. A few studies revealed that a stronger association with mortality
is observed if depressive symptoms were assessed repeatedly instead
of only once at the start of dialysis [6,7]. The relatively weak prognosticgy, Leiden University Medical
00 RB Leiden, The Netherlands.
vier OA license.value of depressive symptoms formortality when depressive symptoms
are assessed only once at the start of dialysis compared with depressive
symptoms assessed repeatedly may be attributed to the temporary ad-
justment to a stressful life event [8,9]. Most patients starting dialysis ex-
perience feelings of uncertainty about the future and grief about the
apparent loss of renal function [10]. The occurrence of negative feelings
however appears to diminish over time for the majority of patients, as
most patients show resilience by adapting to the extensive demands
of day to day dialysis therapy after a while [9,11,12]. Another explana-
tion for why a repeated measure of depressive symptoms seems stron-
ger associated with mortality is that the natural course of depressive
symptoms includes remissions and relapses.
Probably, the various processes that link depressive symptoms and
mortality may preferentially unfold if depressive symptoms persist
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the accumulation of social isolation [12,13], stress [10], and poor health
behaviors, like smoking [14,15], lack of physical exercise [16,17], and a
reduced adherence to medication [18] and ﬂuid restrictions [19].
These health behaviors subsequently increase the risk for mortality.
Besides inﬂuencing health behaviors, the continuous presence of de-
pressive symptoms may be mutually related to a chronic disregulation
of the hypothalamic–pituitary–adrenal (HPA) axis, and chronic inﬂam-
mation, which is associated with an increased risk for mortality as well
[1]. Finally, depressive symptoms may vary over time as a result of the
relative effectiveness of dialysis treatment, and the (lack of) prospect
of a future transplantation.
To date, there is a lack of knowledge regarding whether different
patterns of depressive symptoms are associated with differences in
mortality in patients who receive chronic dialysis therapy. Moreover,
no data are available about whether different courses of depressive
symptoms are pathophysiologically associated with different causes
of mortality. This is of interest since it has been hypothesized that per-
sistent or new-onset depressive symptoms are especially associated
with the pathogenesis of cardiovascular diseases [20,21]. The aim of
the current study was to investigate the association between different
courses of depressive symptoms with both cardiovascular and non-
cardiovascular mortality in a Dutch nation-wide study among incident
patients with ESRD treated with chronic dialysis therapy.
Method
Patients
Data were collected within the framework of The Netherlands
Co-operative Study on the Adequacy of Dialysis (NECOSAD), a pro-
spective observational study among incident patients receiving
hemodialysis (HD) and peritoneal dialysis (PD) in 38 centers in The
Netherlands included between 1997 and 2007. The study was ap-
proved by all local medical ethics committees and all patients gave
written informed consent before inclusion. Patients were included
in NECOSAD if they were≥18 years of age and had no previous histo-
ry of renal replacement therapy. For the present study, we selected all
patients who had survived the ﬁrst 12 months on dialysis and
completed questionnaires about depressive symptoms both at 3 and
12 months after the initiation of dialysis.
Measures
Depressive symptoms were assessed 3 and 12 months after the
start of dialysis using the Mental Health Inventory (MHI). That MHI
is the Mental Health scale of the Medical Outcomes Survey
Short-form 36. The MHI has been validated as a reliable measure of
depressive symptoms in different populations [22–25]. It includes 5
items questioning how often during the past month patients had
felt ‘downhearted and blue’, ‘calm and peaceful’, ‘happy’, ‘nervous’,
and ‘so down in the dumps that nothing could cheer them up’.
Items were scored on a six-point scale, varying from all of the time
to none of the time. The scores were summed and transformed to a
scale ranging from 0 to 100. The reliability of the scale was good (at
3 months Cronbach's α = .84; at 12 months Cronbach's α = .85).
Depressive symptoms were assessed in dichotomous manner using
a cut-off of 52 (depressive symptoms were considered to be present
when the MHI scores were≤52). This cut-off showed a good speciﬁcity
and sensitivity for detecting clinically signiﬁcant depressive symptoms
in patients with chronic illness [26], and has been used previously in
studies in patients on dialysis [6,27,28].
Four courses of depressive symptoms were distinguished: no depres-
sive symptoms (no depressive symptoms at 3 and at 12 months),
baseline depressive symptoms only (only depressive symptoms at
3 months), new-onset depressive symptoms (only depressive symptomsat 12 months), and persistent depressive symptoms (depressive symp-
toms at 3 and at 12 months).
At the start of dialysis, data were collected on sociodemographics
and primary cause of renal disease. The primary cause of kidney disease
was classiﬁed according to the ERA-EDTA coding system [29]. Twelve
months after the start of dialysis, dialysis modality (i.e., HD or PD),
and comorbiditieswere recorded (i.e., the presence of diabetesmellitus,
having a history of myocardial infarction, angina pectoris, congestive
heart failure, peripheral vascular disease, or cerebrovascular accident).
The following data were collected at 12 months after the start of dialy-
sis: residual glomerular ﬁltration rate (rGFR) (calculated as the mean
renal clearance of creatinine and urea corrected for body surface area
(mL/min/1.73 m2)), serum albumin level, hemoglobin, plasma phos-
phorus, intact parathyroid hormone (iPTH), and plasma creatinine.
End points
Causes of death were determined by the patients' nephrologist and
classiﬁed according to the codes of the ERA-EDTA registry [29], which
is widely adopted by nephrologists and renal registries around the
world [30], and has been applied in previous studies [e.g., 31,32]. Car-
diovascularmortality was deﬁned as death due to the following causes:
myocardial ischemia and infarction, hyperkalemia, hypokalemia, cardi-
ac failure, ﬂuid overload, cerebrovascular accident, hemorrhage from a
ruptured vascular aneurysm, cardiac arrest, mesenteric infarction, and
cause of death uncertain/unknown. All other causes of mortality were
designated as being non-cardiovascular, i.e., death due to the following
causes: infection, malignancy, suicide or refusal of further treatment,
cachexia, and miscellaneous.
Statistical analysis
T-tests and chi-square testswere used to compare sociodemographic
and clinical characteristics between (a) patients who completed both
questionnaire and patients who did not complete the questionnaire at
12 months, and (b) patients who did not have depressive symptoms
at 3 and 12 months and patients who reported depressive symptoms
at least once at 3 months or at 12 months (i.e., baseline, new-onset or
persistent). Analyses of variance and chi-square tests were used to
assess differences in patient characteristics between the groups with
depressive symptoms.
Survival time was deﬁned as the number of days between
12 months after starting dialysis and death or censoring, i.e. transfer
to a nonparticipating dialysis center, withdrawal from the study,
renal transplantation, recovery of kidney function, or reaching the
end of the follow-up period at April 2011. Cumulative mortality
curves for cardiovascular mortality and non-cardiovascular mortality
were calculated using competing risk analysis regarding cause of
mortality, as patients dying of cardiovascular causes are no longer at
risk to die of non-cardiovascular causes, and vice versa [33]. Cox
proportional hazards analysis was used to assess the association
between depressive symptoms and all-cause mortality, cardiovascu-
lar mortality, and non-cardiovascular mortality. Hazard ratios (HR)
for mortality with accompanying 95% conﬁdence intervals (95% CI)
were calculated for patients with depressive symptoms at 3 and
12 months, and subsequently for patients with depressive symptoms
at baseline only, new-onset depressive symptoms, and persistent
depressive symptoms with patients without depressive symptoms
as reference group. In addition, HRs of patients who reported depres-
sive symptoms at least at one time point were compared with pa-
tients who did not have depressive symptoms at 3 and 12 months.
Adjustments were made for age, sex, marital status, having children,
ethnicity, educational level, being employed, dialysis modality, pri-
mary cause of renal disease, comorbidities at 12 months (that is, dia-
betes mellitus, angina pectoris, cerebrovascular accident, peripheral
vascular disease, myocardial infarction and congestive heart failure),
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phosphorus, iPTH, and creatinine) determined at 12 months after the
initiation of dialysis. The full set of measures for the adjusted analyses
was available for 64.1% of the patients. Variables had less than 5%
missing values, except for rGFR which was missing for 18.8%. In
order to increase precision of the estimates and to decrease bias miss-
ing values were imputed using multiple imputation techniques
[34,35] using standard multiple imputation methods (10 repetitions)
in SPSS statistical software version 17.0 (SPSS, Chicago, IL). The Cox
regression models were ﬁtted to each of the imputed datasets and re-
sults were averaged by using Rubin's rules [36]. All P-values are
reported two-sided and were considered signiﬁcant at a b0.05 level.
Sensitivity analyses
Several sensitivity analyses were conducted. First, we checked
whether the pattern of results regarding the association with mortality
and depressive symptoms at 3 months and at 12 months remained
similar if depressive symptoms were analyzed as a continuous variable.
Secondly, we ran all analyses after excluding patients ofwhom the cause
of death was unknown. The reason for this is that deaths with an
uncertain/unknown cause, were designated as cardiovascular deaths,
which may lead to an overestimation of the number of cardiovascular
deaths [32]. Third, sensitivity analyses were performed in which we
did not censor for transplantation. The reason for this is that censoring
for transplantationmay introduce selection bias, as patientswho receive
a renal transplant are usually healthier than patients who have not.
Fourth, the presence of baseline depressive symptoms and new-onset
depressive symptoms was determined in a more stringent manner
to avoid classifying patients without meaningful changes over time
(e.g., shifting fromMHI = 53 to MHI = 51 over time). In this analysis,
we respectively excluded patients with depressive symptoms at base-
line only and patients with new-onset depressive symptoms if they
showed a decrease or increase of less than 10 points between 3 months
and 12 months, respectively (10 points equaled 0.5 standard devia-
tion). Finally, sensitivity analyses were conducted to check whether re-
sults are similar if we additionally adjusted for comorbidities, treatment
modality and laboratory values at 3 months (instead of at 12 months
only).
Results
In total, 1528 patients completed the MHI at 3 months, of whom 1077 completed
the 12-month follow-up questionnaire as well. Of the 451 patients who did not com-
plete the questionnaire at 12 months, 215 patients had died, 114 had received a
renal transplantation, and 15 patients had a recovery of renal function. Furthermore,
20 patients were lost because they were transferred to a dialysis center that did not
participate in the NECOSAD study or because their dialysis center discontinued study
participation. Finally, 63 patients refused further participation in the NECOSAD study
and 24 patients were still included in the NECOSAD study but did not complete the
MHI at 12 months. The 87 patients who discontinued participation in the NECOSAD
study or who did not complete the MHI at 12 months had a better renal function
(P = .017) and reported more depressive symptoms at 3 months (P = .025) than
the group of 1077 patients who did complete the follow-up measure. On all other
sociodemographic and clinical characteristics at 3 months, no differences were ob-
served between those two groups.
Depressive symptoms at 3 months and 12 months
Of the 1077 patients who completed both questionnaires, 96 patients had depressive
symptoms at baseline only (8.9%), 97 patients had new-onset depressive symptoms
(9.0%), 117 patients had persistent depressive symptoms (10.9%), and 767 patients had
no depressive symptoms (71.2%).
Table 1 shows sociodemographic and clinical characteristics of the four groups. Pa-
tientswho reported depressive symptoms at least at one time point, differed in several re-
spects from patients without depressive symptoms. Compared with patients without
depressive symptoms, patientswith depressive symptoms at 3 months and/or 12 months
were older (P = .009), more often female (P = .010), lower educated (P b .001), more
often non-employed (P b .001), and more often treated with HD instead of PD (P =
.016). Furthermore, these patients had more comorbidities (diabetes mellitus P b .001,angina pectoris P b .001, cerebrovascular accident P = .022), and lower levels of serum
albumin (P b .001), creatinine (P b .001), and hemoglobin (P = .014).
Patients with persistent depressive symptoms seemed to suffer frommore severe de-
pressive symptoms: At 3 months they reported more severe depressive symptoms than
patients with depressive symptoms at 3 months only (P = .001), and at 12 months
they had more severe depressive symptoms than patients with depressive symptoms at
12 months only (P = .001). Among the three groupswith depressive symptoms patients,
differences were observed regarding serum albumin (P = .047), creatinine (P = .008),
and phosphorus (P = .046). Patients with depressive symptoms at baseline only had
higher levels of serum albumin and lower phosphorus than patients with new-onset or
persistent depressive symptoms. In addition, patients with persistent depressive symp-
toms had a lower level of creatinine than patients with depressive symptoms at baseline
only or new-onset depressive symptoms. No other differences in sociodemographic, clin-
ical and laboratory variables were observed among the three groups with depressive
symptoms.
Depressive symptoms and mortality
Among 1077 study patients, 479 deaths (44.5%) occurred during follow-up, of
which 215 deaths were related to a cardiovascular cause (44.9%). Both at 3 months
and at 12 months depressive symptoms were related to cardiovascular mortality
(3 months HRadj = 1.66, 95% CI 1.19–2.31; 12 months HRadj = 1.82, 95% CI 1.31–
2.53), and non-cardiovascular mortality (3 months HRadj = 1.71, 95% CI 1.28–2.30;
12 months HRadj = 1.49, 95% CI 1.10–2.02). Differences in all-cause, cardiovascular
and non-cardiovascular mortality were observed across the four groups (Fig. 1), with
patients without depressive symptoms having the lowest mortality risk. Compared
with patients without depressive symptoms, patients with depressive symptoms at 3
and/or 12 months had both a higher cardiovascular mortality risk (HRadj = 1.74, 95%
CI 1.28–2.35), and a higher non-cardiovascular mortality risk (HRadj = 1.70, 95% CI
1.29–2.23). Table 2 depicts crude and adjusted HRs for mortality for patients with dif-
ferent courses of depressive symptoms with patients without depressive symptoms as
reference group. After adjustment, patients with depressive symptoms at baseline had
a 1.91-fold (95% CI 1.26–2.90) increased risk for non-cardiovascular mortality com-
pared with patients without depressive symptoms, whereas cardiovascular mortality
was moderately increased (HRadj = 1.41, 95% CI 0.85–2.33). Patients with new-onset
depressive symptoms had a moderately increased risk for cardiovascular mortality
(HRadj = 1.66, 95% CI 1.06–2.58) and an increased risk for non-cardiovascular mortal-
ity (HRadj = 1.46, 95% CI 0.97–2.20). Finally, patients with persistent depressive
symptoms had a 2.14-fold (95% CI 1.42–3.24) increased risk for cardiovascular and a
1.76-fold (95% CI 1.20–2.59) increased risk for non-cardiovascular mortality compared
with patients without depressive symptoms (see Table 2).
Sensitivity analyses
Analyses to assess whether depressive symptoms were associated with mortality
at 3 and at 12 months were repeated with depressive symptoms as a continuous
variable (reversed score). This did not change the pattern of results (cardiovascular
mortality: at 3 months HRadj = 1.0009, 95% CI [1.001–1.016], at 12 months HRadj =
1.015, 95% CI [1.007–1.023]; non-cardiovascular mortality: at 3 months HRadj =
1.014, 95% CI [1.008–1.021], at 12 months HRadj = 1.012, 95% CI [1.005–1.019]).
Secondly, the cause of death was unknown for 87 patients who died during
follow-up. Cox regression analyses in which patients with an unknown cause of
death were excluded did not reveal different results (data not shown). In the third sen-
sitivity analysis we found that 372 patients were censored during follow-up because
they received a kidney transplantation. These patients reported fewer depressive
symptoms at 3 and 12 months than patients who did not receive a renal transplanta-
tion during follow-up (P b .001). Analyses in which we did not censor for transplanta-
tion did not reveal different results (data not shown). Subsequently, we excluded all
patients from the baseline only group (n = 20) and the new-onset group (n = 19)
who showed a decrease, respectively an increase of less than 10 points in the MHI
score. This more stringent designation of depressive symptoms did not change the
pattern of results; only the association between new-onset depressive symptoms
and cardiovascular mortality became somewhat more pronounced (patients with de-
pressive symptoms at baseline only compared with patients without depressive symp-
toms: cardiovascular mortality, HRadj = 1.45, 95% CI 0.82–2.56; non-cardiovascular
mortality, HRadj = 2.02, 95% CI 1.28–3.20; patients with new-onset depressive symp-
toms compared with patients without depressive symptoms: cardiovascular mortality,
HRadj = 1.78, 95% CI 1.10–2.88; non-cardiovascular mortality, HRadj = 1.37, 95% CI
0.87–2.17). In the last sensitivity analysis we found that results did not materially
change when we additionally adjusted for comorbidities, treatment modality and
laboratory values at 3 months (data not shown).
Discussion
Our study adds up to the growing evidence suggesting that de-
pressive symptoms among patients on dialysis are associated with
poor survival [1–5]. In the current study we showed that all patterns
of depressive symptoms over time pose a risk factor for mortality:
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new-onset depressive symptoms, and persistent depressive symp-
toms. This means that patients who were only depressed in the ﬁrst
period after starting dialysis remain at a higher risk for mortality
than patients without depressive symptoms. Interestingly, depressive
symptoms at baseline only, seemed to be a strong marker for espe-
cially non-cardiovascular mortality (1.91-fold increased risk), where-
as cardiovascular mortality was only slightly increased among these
patients. In contrast, new-onset depressive symptoms were moder-
ately associated with both cardiovascular and non-cardiovascular
mortality. Furthermore, patients with persistent depressive symp-
toms seemed to suffer from more severe depressive symptoms at
each time point than patients with depressive symptoms at baseline
only and new-onset depressive symptoms. Persistent depressed
symptoms were strongly associated with both cardiovascular and
non-cardiovascular mortality.
Perhaps different courses of depressive symptoms are associated
with different pathophysiological pathways to explain mortality. De-
pressive symptoms may be harmful from both behavioral and biolog-
ical perspectives. For example, multiple ongoing stressors associated
with chronic dialysis therapy, such as loss of occupation and social
functioning, decreased physical, cognitive and sexual functioning,
and the experience of a decline in kidney function can induce chronic
feelings of hopelessness and depression [1,37]. These persistent
depressive symptoms may lead to mortality by inﬂuencing poor
illness behaviors such as persistence of smoking, and less physical ex-
ercise [14–17]. Depressive symptoms also predict low adherence
rates with medication intake [18] and ﬂuid restrictions [19] in
patients on dialysis, which are risk factors for mortality as wellTable 1
Sociodemographic and clinical characteristics of patients with four patterns of depressive s
No DS
(n = 767)
DS at baselin
(n = 96)
DS continuous MHI score: M (SD)
DS 3 months 79.1 (11.9) 44.6 (7.5)
DS 12 months 79.2 (12.1) 68.1 (11.7)
Sociodemographic characteristics
Age: M (SD) 59.1 (14.9) 60.7 (13.1)
Sex: male (%) 62.4 53.1
Education: low (%) 51.8 66.0
Married: yes (%) 72.2 69.5
Having children: yes (%) 78.1 80.0
Employed: yes (%) 25.6 17.9
Ethnicity: Caucasian (%) 94.9 89.6
Clinical
Modality: hemodialysis (%) 60.1 66.7
Primary cause of disease (%)
Diabetes mellitus 11.4 16.7
Glomerulonephritis 14.9 9.4
Renal vascular disease 15.1 20.8
Other 58.6 53.1
Co-morbidity (%)
Diabetes mellitus 15.3 16.7
Angina pectoris 8.5 21.9
Cerebrovascular accident 6.8 14.6
Peripheral vascular disease 10.6 12.5
Myocardial infarction 8.9 14.6
Congestive heart failure 8.1 10.4
Laboratory and rGFR: M (SD)
Albumin (g/dL) 3.7 (0.5) 3.7 (0.5)
Hemoglobin (g/dL) 11.7 (1.3) 11.4 (1.4)
Phosphorus (mmol/L) 1.8 (0.5) 1.7 (0.5)
iPTH (pmol/L) 20.4 (24.7) 19.9 (27.1)
Creatinine (μmol/L) 884.9 (257.3) 836.9 (259.4
rGFR (mL/min/1.73 m2) 2.9 (2.8) 3.3 (3.5)
Used abbreviations: DS = depressive symptoms; MHI = mental health inventory; M =
intact parathyroid hormone.
a No DS: 3 and 12 months MHI > 52; DS at baseline only: 3 months MHI ≤ 52, 12 months
and 12 months MHI ≤ 52.[38,39]. Besides affecting detrimental illness behaviors, persistent
stress and depressive symptoms seem bi-directionally related to
immune system activity [1,5]. For example, depressive symptoms
are associated with pro-inﬂammatory cytokines [40–42], which may
disregulate the HPA axis by cortisol, resulting in an increase in im-
mune activation [43,44]. Finally, depressive symptoms may be a con-
sequence rather than the cause of a poor medical trajectory. In line
with this, patients with depressive symptoms at 3 and/or 12 months
had more often comorbidities (e.g., diabetes mellitus), and showed
lower levels of albumin, creatinine, and hemoglobin. Although adjust-
ed analyses controlled for a wide array of sociodemographic, medical
and laboratory characteristics, it is still possible that prevalent or inci-
dent disease characteristics explain a part of the association between
depressive symptoms and mortality.
More in-depth knowledge on characteristics of the relation between
depressive symptoms and mortality (e.g. course, speciﬁc cause of mor-
tality, short-term vs long-term effects on mortality) may also help to
understand whether speciﬁc treatment strategies may be beneﬁcial to
patients. For example, it has been suggested that new-onset depressive
symptoms in patients with myocardial infarction represent depressive
symptoms with a different etiology. This type of depressive symptoms
is associated with ongoing arteriovascular damage and a high cardio-
vascularmortality [45,46]. These patients seem to be resistant to several
conventional psychiatric treatments for depression [46], as the type of
depressive symptoms seems rather a symptom of detrimental cardio-
vascular disease than a conventional depressive disorder. In contrast,
patients with other patterns of depressive symptoms may experience
larger beneﬁts from conventional depression treatment. For example,
a multidisciplinary treatment intervention focusing on patients withymptoms (DS)a
e only New-onset DS
(n = 117)
Persistent DS
(n = 97)
P
67.7 (11.3) 39.6 (12.7) b .001
43.9 (8.2) 39.4 (11.8) b .001
61.5 (12.7) 62.0 (13.0) .089
59.8 49.6 .029
64.9 67.0 b .001
75.3 69.2 .744
77.1 78.1 .968
9.5 9.7 b .001
92.8 94.0 .002
66.0 70.7 .096
16.5 20.5 .022
14.4 13.7 .541
18.6 14.5 .431
50.5 51.3 .208
26.8 27.6 b .001
22.7 19.8 b .001
7.2 11.2 .031
14.4 16.4 .248
9.3 11.2 .319
8.2 11.1 .743
3.6 (0.5) 3.6 (0.5) b .001
11.4 (1.6) 11.5 (1.7) .063
1.9 (0.6) 1.9 (0.6) .023
23.3 (29.9) 17.0 (20.6) .342
) 871.3 (240.5) 767.8 (241.9) b .001
2.3 (2.6) 3.2 (3.2) .117
mean; SD = standard deviation; rGFR = residual glomerular ﬁltration rate; iPTH =
MHI > 52; New-onset DS: 3 months MHI > 52, 12 months MHI ≤ 52; persistent DS: 3
Table 2
Patterns of depressive symptoms (DS)a and hazard ratios for all-cause, cardiovascular
and non-cardiovascular mortality with patients without depressive symptoms as refer-
ence group
Crude Adjustedb
HR [95% CI] P HR [95% CI] P
DS at baseline only
All-cause mortality 1.44 [1.06–1.95] .020 1.66 [1.20–2.29] .002
Cardiovascular mortality 1.25 [0.77–2.02] .363 1.41 [0.85–2.33] .182
Non-cardiovascular mortality 1.59 [1.07–2.36] .021 1.91 [1.26–2.90] .002
New-onset DS
All-cause mortality 1.85 [1.39–2.46] b .001 1.54 [1.14–2.08] .005
Cardiovascular mortality 1.89 [1.24–2.88] .003 1.66 [1.06–2.58] .026
Non-cardiovascular mortality 1.81 [1.23–2.68] .003 1.46 [0.97–2.20] .070
Persistent DS
All-cause mortality 2.49 [1.92–3.23] b .001 1.93 [1.46–2.57] b .001
Cardiovascular mortality 2.56 [1.75–3.74] b .001 2.14 [1.42–3.24] b .001
Non-cardiovascular mortality 2.44 [1.71–3.48] b .001 1.76 [1.20–2.59] .004
a No DS: 3 and 12 months MHI > 52; DS at baseline only: 3 months MHI ≤ 52,
12 months MHI > 52; New-onset DS: 3 months MHI > 52, 12 months MHI ≤ 52;
persistent DS: 3 and 12 months MHI ≤ 52.
b Adjusted for age, sex, marital status, having children, ethnicity, educational level,
being employed, primary cause of renal disease, dialysis modality, the presence of
diabetes mellitus, having a prior history of myocardial infarction, angina pectoris,
congestive heart failure, peripheral vascular disease, or cerebrovascular accident at
12 months, and hemoglobin, iPTH, plasma phosphorus, serum albumin, rGFR, and
creatinine at 3 and 12 months.
Fig. 1. Cumulative mortality curves for all-cause (a), cardiovascular (b), and non-
cardiovascular (c) mortality for patients with different patterns of depressive
symptoms.
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isode of depressive symptoms showed promising effects in patients
with acute coronary syndrome [47].
The association between different time patterns of depressive
symptoms and cardiovascular and non-cardiovascular mortality
raises the question whether an adequate screening and treatment of
depressive symptoms will improve the mortality in patients on dialy-
sis. Meta-analyses in other chronic ill patient cohorts show that there
is no evidence to date that routinely screening for and subsequently
treating depressive symptoms enhances survival [48,49]. However,
ameliorating depressive symptoms is in itself a valid therapeutic
goal [2]. With an estimated prevalence of above threshold depressive
symptoms being between 20% and 30%, the burden of depressive
symptoms among patients on dialysis is extensive [1], whereas only
a small minority of patients are adequately diagnosed and treated
for depressive symptoms [2]. A reason why physicians may fail to rec-
ognize depressive symptoms is related to the considerable overlap
between somatic depressive symptoms and the burden of uremic
symptoms of chronic dialysis, such as decreased appetite, lack of
energy, concentrating difﬁculties, and sleep disturbance [1]. Thisrequires physicians to be aware of accompanying cognitive depres-
sive symptoms, such as feelings of guilt, worthlessness, or suicidal
thoughts as well [1,2]. Moreover, individuals who are vulnerable to
depression will exhibit persistent negative biases in their thinking
style [50]. A better recognition of the combination of cognitive and
somatic depressive symptoms in patients on dialysis and whether
they persist over time is needed.
Speciﬁc strengths of the current study are the nation-wide pro-
spective study design with incident patients on dialysis, and the rela-
tively large sample of patients with ESRD. Some limitations of the
current study should also be noted. First, we relied on the MHI as
measure of depressive symptoms. Although the MHI has been vali-
dated as a sound measure of depressive symptoms [22–25], the
scale only measures a limited set of depressive symptoms and is not
as commonly employed as, for example, the Beck Depression Invento-
ry. However, a speciﬁc strength of the MHI is that it does not include
somatic symptoms that can be attributed to both uremic symptoms of
dialysis as well as to depressive symptoms. A practical advantage of
the MHI is the brief format which makes it feasible for recurrent
assessments in standard care protocols [51]. A second limitation is
that we designed the four groups of depressive symptom courses
based on measures at 3 and 12 months. This means that we only
selected patients who had survived and who were not transplanted
for at least one year after starting dialysis therapy. In addition to
this possible selection bias, relevant information is lost by dichoto-
mizing scores. Although it does make sense from a clinical point of
view to classify patients as ‘non-depressed’ vs ‘depressed’, it can be
questioned whether an objective deﬁnition of different courses over
time can be obtained by applying a simple cut-off measure to identify
clinically signiﬁcant depressive symptoms which is based on two
measurements. Moreover, patients may have had depressive symp-
toms before starting dialysis already or may suffer from intermittent
depressive symptoms. Finally, our results regarding the speciﬁc
cause of mortality should be interpreted with some caution, as the
conﬁdence intervals were rather wide. Future studies may consider
taking into account a larger sample of patients with more frequent
measurements over time to distinguish between patients with differ-
ent courses of depressive symptoms.
516 S. van Dijk et al. / Journal of Psychosomatic Research 74 (2013) 511–517In conclusion, different courses of depressive symptoms seem to
be markers of mortality. The current study shows that even patients
with depressive symptoms at the start of dialysis only are at increased
risk for mortality.
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